| Project/Area Number |
18K08646
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55020:Digestive surgery-related
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
Nagano Hiroaki 山口大学, 大学院医学系研究科, 教授 (10294050)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
恒富 亮一 山口大学, 医学部附属病院, 講師 (10420514)
松隈 聰 山口大学, 医学部附属病院, 助教 (10634743)
徳光 幸生 山口大学, 医学部, 助教(寄附講座等) (40593299)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | 癌幹細胞 / 膵癌 / 癌周辺微小環境 / 形質転換 / 腫瘍微小環境 / 個別化医療 |
|---|
| Outline of Final Research Achievements |
We have developed a method for inducing pancreatic cancer stem cell-like cells (P-CSLC) and reported that calreticulin (CRT) is a novel marker for cancer stem cells. In this study, we applied this result and identified a new therapeutic target potential for pancreatic cancer stem cells through a comprehensive approach of proteomics and mRNA analysis using a next-generation sequencer. In particular, we identified several types of molecules highly expressed in CRT-positive P-CSLC by a comprehensive approach and activated metabolic pathways in the same cells, and showed their potential as therapeutic targets. Furthermore, we were able to analyze the surface antigens associated with P-CSLC and cancer associated fibroblasts (CAFs).
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により解明された膵癌の治療抵抗性に関する知見は、癌幹細胞とも強く関連していると推察されるだけでなく、CAFや免疫逃避機構と癌幹細胞の関与についての可能性までをも追求してきた。
このことによる、膵癌の治療成績向上におけるこれらの機序解明の学術的意義は高い。
|
